Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate
The authors studied the effect of the combination of binders on the flow and compressibility characteristics of the agglomerates of binary combination of lactose and dibasic calcium phosphate dihydrate.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 54-64

7. J.I. Wells, D.A. Bhatt, and K.A. Khan, "Improved Wet Massed Tableting using Plasticized Binder," J. Pharm. Pharmacol. 34 (suppl.), 46P (1982).

8. T. Abberger, "Influence of Binder Properties, Method of Addition, Powder Type and Operating Conditions on Fluid Melt Granulation and Resulting Tablet Properties," Pharmazie 56 (12), 949–952 (2001).

9. S.K. Joneja et al., "Investigating the Fundamental Effects of Binder on Pharmaceutical Tablet Performance," Drug Dev. Ind. Pharm. 25 (10), 129–135 (1999).

10. M.C. Gohel and P.D. Jogani, "Exploration of Melt Granulation Technique for the Development of Coprocessed Directly Compressible Adjuvant Containing Lactose and Microcrystalline Cellulose," Pharm. Dev. Technol. 8 (2), 143–151 (2003).

11. L. Rambali et al., "Using Experimental Design to Optimize the Process Parameters in Fluidized-Bed Granulation," Drug Dev. Ind. Pharm. 27 (1), 47–55 (2001).

12. S.I. Badway et al., "Effect of Process Parameters on Compressibility of Granulation Manufactured in a High-Shear Mixer," Int. J. Pharm. 198 (1), 51–61 (2000)

13. A. Cannon and K. Shemeley, "Statistical Evaluation of Vial Design Features that Influence Sublimation Rate during Primary Drying," Pharm. Res. 21 (3), 536–542 (2004).

14. W. Sibanda et al., "Experimental Design for the Formulation and Optimization of Novel Cross-Linked Oilispheres Developed for In Vitro Site-Specific Release of Mentha Piperita Oil," AAPS PharmSciTech. 5 (1), E18, 2004.

15. J.Z. Li et al., "The Role of Intra- and Extragranular Microcrystalline Cellulose in Tablet Dissolution," Pharm. Dev. Technol. 1 (4), 343–355 (1996).

16. A.Mckenna and D. F. McCafferty, "Effect of Particle Size on the Compaction Mechanism and Tensile Strength of Tablets," J. Pharm. Pharmacol. 34 (6), 347–351 (1982).

17. R.L. Carr, "Evaluating Flow Properties of Solids," Chem. Eng. 72, 163–168 (1965).

18. "Friability," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 2148.

19. "Disintegration Time," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 1941.

20. "Acetaminophen Tablets," in USP 24–NF 19 (United States Pharmacopoeial Convention, Rockville, MD, 2000), p. 20.

21. K.I. Chukwu and O.K. Udeala, "Binding Effectiveness of Colocassia esculenta Gum in Poorly Compressible Drugs: Acetaminophen and Metronidazole Tablet Formulation," Boll. Chim. Farm. 139 (2), 89–97 (2000).

22. S. Mattsson and C. Nystrom, "Evaluation of Critical Binder Properties Affecting the Compactibility of Binary Mixtures," Drug Dev. Ind. Pharm. 27 (3), 181–194 (2001).

23. R.L. Arellano, "Study of Load Capacity of Avicel PH-200 and Cellactose, Two Direct Compression Excipients Using Experimental Design," Drug Dev. Ind. Pharm. 26 (4), 465–469 (2000).

24. S.K. Nachaegari and A.K. Bansal, "Coprocessed Excipients for Solid Dosage Forms," Pharm. Technol. 28 (1), 32–42 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here